Singapore markets closed

  • Straits Times Index

    3,217.41
    +10.42 (+0.32%)
     

  • Nikkei

    31,857.62
    -14.90 (-0.05%)
     

  • Hang Seng

    17,809.66
    +436.63 (+2.51%)
     

  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     

  • Bitcoin USD

    27,020.19
    +111.07 (+0.41%)
     

  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     

  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     

  • Dow

    33,507.50
    -158.84 (-0.47%)
     

  • Nasdaq

    13,219.32
    +18.05 (+0.14%)
     

  • Gold

    1,864.60
    -14.00 (-0.75%)
     

  • Crude Oil

    90.77
    -0.94 (-1.02%)
     

  • 10-Yr Bond

    4.5730
    -0.0240 (-0.52%)
     

  • FTSE Bursa Malaysia

    1,424.17
    -15.94 (-1.11%)
     

  • Jakarta Composite Index

    6,939.89
    +2.06 (+0.03%)
     

  • PSE Index

    6,321.24
    -64.28 (-1.01%)
     

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Alex Carchidi, The Motley Fool
·5-min read
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Most pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers Squibb, (NYSE: BMY) and both businesses have a lot to offer passive income investors too. As one of the world's most preeminent pharma conglomerates, Eli Lilly and its portfolio of products covers all sorts of illnesses, including Alzheimer's disease, diabetes, and different cancers. It also has 21 programs in phase 3 clinical trials, and another 21 in phase 2 trials.

Continue reading